Canaccord Genuity Maintains Buy on TransMedics Group, Lowers Price Target to $94
Canaccord Genuity analyst Jason Mills maintains TransMedics Group (NASDAQ:TMDX) with a Buy and lowers the price target from $95 to $94.
Share
Why It Matters
A stock analyst still likes TransMedics Group and thinks it's worth buying. But the analyst lowered their price target by one dollar, suggesting slightly less growth ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.